Health Condition 1: H351- Retinopathy of prematurity
Conditions
Interventions
Intervention1: Intra vitreal Anti-Vascular Endothelial Growth Factor Inhibitor: dose- 0.25 mg/0.025 ml
route- Intravitreal
Frequency- Once
Control Intervention1: Nil: Nil
Sponsors
Maulana Azad Medical College Guru Nanak Eye Centre
Eligibility
Inclusion criteria
Inclusion criteria: Aggressive ROP (AROP) Zone 1 any stage with plus disease Zone 2 stage2/3 with plus disease.
Exclusion criteria
Exclusion criteria: ? Prior history of anti-VEGF injection ? Prior treatment with laser for ROP ? Any Known hypersensitivity for anti-VEGF injection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change in IOP measured by iCare tonometer at 5 minutes, 15 minutes or until IOP normalizes, on post injection day 1 in the eye receiving intravitreal anti-VEGF injection of ranibizumab under topical anesthesia.Timepoint: 5 minutes 15 minutes post injection Day 1 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Mean change in IOP measured by iCare tonometer at 1 & 3 months in the eye receiving intravitreal anti-VEGF injection of Ranibizumab under topical anesthesia. 2. Response to treatment in terms of serial change in zone & stage of ROP from baseline with or without additional treatment. Timepoint: 1 month 3 month | — |
Countries
India
Contacts
Public ContactRishita Yadav
Department of Ophthalmology Maulana Azad Medical College Guru Nanak Eye Centre
Outcome results
None listed